165 related articles for article (PubMed ID: 28245381)
21. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
22. [Effects of Arsenic Trioxide on K562 Cell Proliferation and Its Mechanisms].
Wang FP; Zhang JJ; Fang LM; Zhang YL; Chen LL; Zhang YY; Li JP; Wang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1725-1729. PubMed ID: 28024484
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
24. Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.
Li Y; Feng L; Li Y; Jiang W; Shan N; Wang X
Leuk Lymphoma; 2014 Jun; 55(6):1366-72. PubMed ID: 23906016
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide inhibits proliferation in K562 cells by changing cell cycle and survivin expression.
Wu X; Chen Z; Liu Z; Zhou H; You Y; Li W; Zou P
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(4):342-4, 353. PubMed ID: 15587394
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells.
Li H; Wang Y; Xu W; Dong L; Guo Y; Bi K; Zhu C
Acta Haematol; 2015; 133(1):18-25. PubMed ID: 24993472
[TBL] [Abstract][Full Text] [Related]
27. [Effect of Quercetin on Wnt/β-Catenin Signal Pathway of K562 and K562R Cells].
Li W; Zhao Y; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1409-1415. PubMed ID: 31607291
[TBL] [Abstract][Full Text] [Related]
28. [The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms].
Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):438-43. PubMed ID: 18072624
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between mTOR signaling transduction pathway and arsenic trioxide response].
Jiang F; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):54-6. PubMed ID: 20137118
[TBL] [Abstract][Full Text] [Related]
30. Apoptotic effect of As2S2 on K562 cells and its mechanism.
Li JE; Wu WL; Wang ZY; Sun GL
Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
32. [Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells].
Chen NY; Wang J; Wang XM; Zhang HX; Yan ZY; Wang YM; Zhang S; Yan B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):882-6. PubMed ID: 20723293
[TBL] [Abstract][Full Text] [Related]
33. Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia.
Jing HM; Yukihiro S; Ke XY; Yoshiro K; Akiharu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):413-8. PubMed ID: 12513739
[TBL] [Abstract][Full Text] [Related]
34. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Guo-Bao W; Xiao-Qin C; Qi-Rong G; Jie L; Gui-Nan L; Yue L
Leuk Lymphoma; 2010 Jun; 51(6):1090-7. PubMed ID: 20470221
[TBL] [Abstract][Full Text] [Related]
35. [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang R; Li X; Huang X; Yang X; Li W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 34(6):515-22. PubMed ID: 19587434
[TBL] [Abstract][Full Text] [Related]
36. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
37. The influence of arsenic trioxide on the cell cycle, apoptosis and expression of cyclin D1 in the Jurkat cell line.
Zuryń A; Litwiniec A; Gagat M; Drzewucka J; Gackowska L; Grzanka A
Acta Histochem; 2014 Oct; 116(8):1350-8. PubMed ID: 25258011
[TBL] [Abstract][Full Text] [Related]
38. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Wang Y; An R; Dong X; Pan S; Duan G; Sun X
Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
[TBL] [Abstract][Full Text] [Related]
40. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
